Genetics/epigenetics of oral premalignancy: Current status and future research

Oral Diseases

Volumn 17, Issue SUPPL. 1, 2011, Pages 7-22

  Lingen, Mw ^a   Pinto, A ^b,c   Mendes, Ra ^d   Franchini, R ^e,f   Czerninski, R ^g   Tilakaratne, Wm ^h   Partridge, M ⁱ   Peterson, De ^j   Woo, S B ^k  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF PENNSYLVANIA SCHOOL OF DENTAL MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Portuguese Catholic University Viseu   (Portugal)

^e UNIVERSITY OF MILAN   (Italy)

^f UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^g HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^h UNIVERSITY OF PERADENIYA   (Sri Lanka)

ⁱ KING'S COLLEGE LONDON   (United Kingdom)

^j UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^k BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

Genetics; Oral; Premalignancy

Indexed keywords

CYCLIN D1; CYCLINE; DEATH ASSOCIATED PROTEIN KINASE; EPIDERMAL GROWTH FACTOR; GLUTATHIONE TRANSFERASE P1; KI 67 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICRORNA 21; MINICHROMOSOME MAINTENANCE PROTEIN 2; MITOGEN ACTIVATED PROTEIN KINASE; NERVE GROWTH FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53; PROTEIN P63; PROTEIN P73; RETINOBLASTOMA PROTEIN; TELOMERASE; TRANSFORMING GROWTH FACTOR ALPHA; VASCULOTROPIN;

ALLELIC IMBALANCE; ANEUPLOIDY; ARTICLE; CANCER DIAGNOSIS; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; CHROMOSOME 14P; CHROMOSOME 16P; DNA METHYLATION; EPIGENETICS; GENETIC ASSOCIATION; HETEROZYGOSITY LOSS; HISTONE MODIFICATION; HUMAN; MALIGNANT TRANSFORMATION; MICROSATELLITE INSTABILITY; MOUTH CARCINOMA; MOUTH SQUAMOUS CELL CARCINOMA; PRECANCER; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; DENTAL RESEARCH; EPIGENESIS, GENETIC; EPIGENOMICS; FORECASTING; HUMANS; MOUTH NEOPLASMS; PRECANCEROUS CONDITIONS; TUMOR MARKERS, BIOLOGICAL;

EID: 79952520899     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2011.01789.x     Document Type: Article

References (180)

1. Abbey LM, Kaugars GE, Gunsolley JC et al (1995). Intraexaminer and interexaminer reliability in the diagnosis of oral epithelial dysplasia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 80: 188-191.
2. Abou-Elhamd KE, Habib TN (2007). The flow cytometric analysis of premalignant and malignant lesions in head and neck squamous cell carcinoma. Oral Oncol 43: 366-372.
3. Amornphimoltham P, Sriuranpong V, Patel V et al (2004). Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin Cancer Res 10: 4029-4037.
4. Arduino PG, Surace A, Carbone M et al (2009). Outcome of oral dysplasia: a retrospective hospital-based study of 207 patients with a long follow-up. J Oral Pathol Med 38: 540-544.
5. Baretton G, Li X, Stoll C, Fischer-Brandies E, Schmidt M, Lohrs U (1995). Prognostic significance of DNA ploidy in oral squamous cell carcinomas. A retrospective flow and image cytometric study with comparison of DNA ploidy in excisional biopsy specimens and resection specimens, primary, tumors, and lymph node metastases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 79: 68-76.
6. Bergler W, Bier H, Ganzer U (1989). The expression of epidermal growth factor receptors in the oral mucosa of patients with oral cancer. Arch Otorhinolaryngol 246: 121-125.
7. Blot WJ, McLaughlin JK, Winn DM et al (1988). Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 48: 3282-3287.
8. Bortoluzzi MC, Yurgel LS, Dekker NP, Jordan RC, Regezi JA (2004). Assessment of p63 expression in oral squamous cell carcinomas and dysplasias. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 98: 698-704.
9. Bradley KT, Budnick SD, Logani S (2006). Immunohistochemical detection of p16INK4a in dysplastic lesions of the oral cavity. Mod Pathol 19: 1310-1316.
10. Bremmer JF, Braakhuis BJ, Ruijter-Schippers HJ et al (2005). A noninvasive genetic screening test to detect oral preneoplastic lesions. Lab Invest 85: 1481-1488.
11. Bremmer JF, Braakhuis BJ, Brink A et al (2008). Comparative evaluation of genetic assays to identify oral pre-cancerous fields. J Oral Pathol Med 37: 599-606.
12. Brennan PA, Conroy B, Spedding AV (2000). Expression of inducible nitric oxide synthase and p53 in oral epithelial dysplasia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 90: 624-629.
13. Califano J, van der Riet P, Westra W et al (1996). Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 56: 2488-2492.
14. Califano J, Westra WH, Meininger G, Corio R, Koch WM, Sidransky D (2000). Genetic progression and clonal relationship of recurrent premalignant head and neck lesions. Clin Cancer Res 6: 347-352.
15. Carlile J, Harada K, Baillie R et al (2001). Vascular endothelial growth factor (VEGF) expression in oral tissues: possible relevance to angiogenesis, tumour progression and field cancerisation. J Oral Pathol Med 30: 449-457.
16. Cervigne NK, Reis PP, Machado J et al (2009). Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma. Hum Mol Genet 18: 4818-4829.
17. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML (2008). Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 26: 612-619.
18. Chen Q, Luo G, Li B, Samaranayake LP (1999). Expression of p16 and CDK4 in oral premalignant lesions and oral squamous cell carcinomas: a semi-quantitative immunohistochemical study. J Oral Pathol Med 28: 158-164.
19. Chen YK, Hsue SS, Lin LM (2004). p73 expression for human buccal epithelial dysplasia and squamous cell carcinoma: does it correlate with nodal status of carcinoma and is there a relationship with malignant change of epithelial dysplasia? Head Neck 26: 945-952.
20. Chen L, Wong MP, Cheung LK, Samaranayake LP, Baum L, Samman N (2005a). Frequent allelic loss of 21q11.1 approximately q21.1 region in advanced stage oral squamous cell carcinoma. Cancer Genet Cytogenet 159: 37-43.
21. Chen YK, Hsue SS, Lin LM (2005b). Expression of p63 protein and mRNA in oral epithelial dysplasia. J Oral Pathol Med 34: 232-239.
22. Chen HH, Yu CH, Wang JT et al (2007). Expression of human telomerase reverse transcriptase (hTERT) protein is significantly associated with the progression, recurrence and prognosis of oral squamous cell carcinoma in Taiwan. Oral Oncol 43: 122-129.
23. Cheng YS, Wright JM (2005). Oral and maxillofacial pathology case of the month. Focal cemento-osseous dysplasia. Tex Dent J 122: 986-987.
24. Choi HR, Tucker SA, Huang Z et al (2003). Differential expressions of cyclin-dependent kinase inhibitors (p27 and p21) and their relation to p53 and Ki-67 in oral squamous tumorigenesis. Int J Oncol 22: 409-414.
25. Christensen ME (1998). The EGF receptor system in head and neck carcinomas and normal tissues. Immunohistochemical and quantitative studies. Dan Med Bull 45: 121-134.
26. Ciardiello F, Tortora G (2003). Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 39: 1348-1354.
27. Cobb MH, Goldsmith EJ (1995). How MAP kinases are regulated. J Biol Chem 270: 14843-14846.
28. Cruz IB, Snijders PJ, Meijer CJ et al (1998). p53 expression above the basal cell layer in oral mucosa is an early event of malignant transformation and has predictive value for developing oral squamous cell carcinoma. J Pathol 184: 360-368.
29. Denhart BC, Guidi AJ, Tognazzi K, Dvorak HF, Brown LF (1997). Vascular permeability factor/vascular endothelial growth factor and its receptors in oral and laryngeal squamous cell carcinoma and dysplasia. Lab Invest 77: 659-664.
30. Diwakar N, Sperandio M, Sherriff M, Brown A, Odell EW (2005). Heterogeneity, histological features and DNA ploidy in oral carcinoma by image-based analysis. Oral Oncol 41: 416-422.
31. Donadini A, Maffei M, Cavallero A et al (2010). Oral cancer genesis and progression: DNA near-diploid aneuploidization and endoreduplication by high resolution flow cytometry. Cell Oncol 32: 373-383.
32. D'Souza G, Kreimer AR, Viscidi R et al (2007). Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356: 1944-1956.
33. Egger G, Liang G, Aparicio A, Jones PA (2004). Epigenetics in human disease and prospects for epigenetic therapy. Nature 429: 457-463.
34. El-Naggar AK, Coombes MM, Batsakis JG, Hong WK, Goepfert H, Kagan J (1998). Localization of chromosome 8p regions involved in early tumorigenesis of oral and laryngeal squamous carcinoma. Oncogene 16: 2983-2987.
35. Epstein JB, Zhang L, Poh C, Nakamura H, Berean K, Rosin M (2003). Increased allelic loss in toluidine blue-positive oral premalignant lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95: 45-50.
36. Erber R, Klein W, Andl T et al (1997). Aberrant p21(CIP1/WAF1) protein accumulation in head-and-neck cancer. Int J Cancer 74: 383-389.
37. Fakhry C, Westra WH, Li S et al (2008). Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100: 261-269.
38. Fourati A, El May MV, Ben Abdallah M et al (2009). Prognostic evaluation of p53, heat shock protein 70, Ki67, and CD34 expression in cancer of the tongue in Tunisia. J Otolaryngol Head Neck Surg 38: 191-196.
39. Fujieda S, Inuzuka M, Tanaka N et al (1999). Expression of p27 is associated with Bax expression and spontaneous apoptosis in oral and oropharyngeal carcinoma. Int J Cancer 84: 315-320.
40. Fujita N, Tsuruo T (2003). Survival-signaling pathway as a promising target for cancer chemotherapy. Cancer Chemother Pharmacol 52(Suppl 1): S24-S28.
41. Fujita H, Nagata M, Hoshina H et al (2004). Clinical significance and usefulness of quantification of telomerase activity in oral malignant and nonmalignant lesions. Int J Oral Maxillofac Surg 33: 693-699.
42. Garnis C, Coe BP, Ishkanian A, Zhang L, Rosin MP, Lam WL (2004). Novel regions of amplification on 8q distinct from the MYC locus and frequently altered in oral dysplasia and cancer. Genes Chromosomes Cancer 39: 93-98.
43. Garnis C, Rosin MP, Zhang L, Lam WL (2005). Alteration of AKAP220, an upstream component of the Rb pathway, in oral carcinogenesis. Int J Cancer 116: 813-819.
44. Garnis C, Chari R, Buys TP et al (2009). Genomic imbalances in precancerous tissues signal oral cancer risk. Mol Cancer 8: 50.
45. Gillison ML, Koch WM, Capone RB et al (2000). Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92: 709-720.
46. Gillison ML, D'Souza G, Westra W et al (2008). Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 100: 407-420.
47. Goldenberg D, Harden S, Masayesva BG et al (2004). Intraoperative molecular margin analysis in head and neck cancer. Arch Otolaryngol Head Neck Surg 130: 39-44.
48. Gologan O, Barnes EL, Hunt JL (2005). Potential diagnostic use of p16INK4A, a new marker that correlates with dysplasia in oral squamoproliferative lesions. Am J Surg Pathol 29: 792-796.
49. Gonzalez MV, Pello MF, Lopez-Larrea C, Suarez C, Menendez MJ, Coto E (1995). Loss of heterozygosity and mutation analysis of the p16 (9p21) and p53 (17p13) genes in squamous cell carcinoma of the head and neck. Clin Cancer Res 1: 1043-1049.
50. Gonzalez-Moles MA, Ruiz-Avila I, Rodriguez-Archilla A, Martinez-Lara I (2000). Suprabasal expression of Ki-67 antigen as a marker for the presence and severity of oral epithelial dysplasia. Head Neck 22: 658-661.
51. Grandis JR, Tweardy DJ (1993). Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53: 3579-3584.
52. Guo Z, Yamaguchi K, Sanchez-Cespedes M, Westra WH, Koch WM, Sidransky D (2001). Allelic losses in OraTest-directed biopsies of patients with prior upper aerodigestive tract malignancy. Clin Cancer Res 7: 1963-1968.
53. Gutkind JS (1998). The pathways connecting G protein-coupled receptors to the nucleus through divergent mitogen-activated protein kinase cascades. J Biol Chem 273: 1839-1842.
54. Ha PK, Califano JA (2006). Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. Lancet Oncol 7: 77-82.
55. Ha PK, Pilkington TA, Westra WH, Sciubba J, Sidransky D, Califano JA (2002). Progression of microsatellite instability from premalignant lesions to tumors of the head and neck. Int J Cancer 102: 615-617.
56. Hasina R, Whipple ME, Martin LE, Kuo WP, Ohno-Machado L, Lingen MW (2008). Angiogenic heterogeneity in head and neck squamous cell carcinoma: biological and therapeutic implications. Lab Invest 88: 342-353.
57. Hemmer J, Nagel E, Kraft K (1999). DNA aneuploidy by flow cytometry is an independent prognostic factor in squamous cell carcinoma of the oral cavity. Anticancer Res 19: 1419-1422.
58. Holmstrup P, Vedtofte P, Reibel J, Stoltze K (2006). Long-term treatment outcome of oral premalignant lesions. Oral Oncol 42: 461-474.
59. Huang M, Spitz MR, Gu J et al (2006). Cyclin D1 gene polymorphism as a risk factor for oral premalignant lesions. Carcinogenesis 27: 2034-2037.
60. Iamaroon A, Khemaleelakul U, Pongsiriwet S, Pintong J (2004). Co-expression of p53 and Ki67 and lack of EBV expression in oral squamous cell carcinoma. J Oral Pathol Med 33: 30-36.
61. Inoue K, Ozeki Y, Suganuma T, Sugiura Y, Tanaka S (1997). Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression. Cancer 79: 206-213.
62. Ishida K, Ito S, Wada N et al (2007). Nuclear localization of beta-catenin involved in precancerous change in oral leukoplakia. Mol Cancer 6: 62.
63. Islam MN, Kornberg L, Veenker E, Cohen DM, Bhattacharyya I (2010). Anatomic site based ploidy analysis of oral premalignant lesions. Head Neck Pathol 4: 10-14.
64. Jiang WW, Fujii H, Shirai T, Mega H, Takagi M (2001). Accumulative increase of loss of heterozygosity from leukoplakia to foci of early cancerization in leukoplakia of the oral cavity. Cancer 92: 2349-2356.
65. Johnstone S, Logan RM (2006). The role of vascular endothelial growth factor (VEGF) in oral dysplasia and oral squamous cell carcinoma. Oral Oncol 42: 337-342.
66. Johnstone S, Logan RM (2007). Expression of vascular endothelial growth factor (VEGF) in normal oral mucosa, oral dysplasia and oral squamous cell carcinoma. Int J Oral Maxillofac Surg 36: 263-266.
67. Jordan RC, Bradley G, Slingerland J (1998). Reduced levels of the cell-cycle inhibitor p27Kip1 in epithelial dysplasia and carcinoma of the oral cavity. Am J Pathol 152: 585-590.
68. Kahn MA, Dockter ME, Hermann-Petrin JM (1994). Proliferative verrucous leukoplakia. Four cases with flow cytometric analysis. Oral Surg Oral Med Oral Pathol 78: 469-475.
69. Kato K, Hara A, Kuno T et al (2006). Aberrant promoter hypermethylation of p16 and MGMT genes in oral squamous cell carcinomas and the surrounding normal mucosa. J Cancer Res Clin Oncol 132: 735-743.
70. Kaur J, Sawhney M, Dattagupta S, Shukla NK, Srivastava A, Ralhan R (2010). Clinical significance of phosphatidyl inositol synthase overexpression in oral cancer. BMC Cancer 10: 168.
71. Kayahara H, Yamagata H, Tanioka H, Miki T, Hamakawa H (2001). Frequent loss of heterozygosity at 3p25-p26 is associated with invasive oral squamous cell carcinoma. J Hum Genet 46: 335-341.
72. Kim HR, Christensen R, Park NH, Sapp P, Kang MK (2001). Elevated expression of hTERT is associated with dysplastic cell transformation during human oral carcinogenesis in situ. Clin Cancer Res 7: 3079-3086.
73. Klanrit P, Sperandio M, Brown AL et al (2007). DNA ploidy in proliferative verrucous leukoplakia. Oral Oncol 43: 310-316.
74. Kodani I, Shomori K, Osaki M, Kuratate I, Ryoke K, Ito H (2001). Expression of minichromosome maintenance 2 (MCM2), Ki-67, and cell-cycle-related molecules, and apoptosis in the normal-dysplasia-carcinoma sequence of the oral mucosa. Pathobiology 69: 150-158.
75. Kodani I, Osaki M, Shomori K et al (2003). Minichromosome maintenance 2 expression is correlated with mode of invasion and prognosis in oral squamous cell carcinomas. J Oral Pathol Med 32: 468-474.
76. Kovesi G, Szende B (2006). Prognostic value of cyclin D1, p27, and p63 in oral leukoplakia. J Oral Pathol Med 35: 274-277.
77. Kresty LA, Mallery SR, Knobloch TJ et al (2002). Alterations of p16(INK4a) and p14(ARF) in patients with severe oral epithelial dysplasia. Cancer Res 62: 5295-5300.
78. Kudo Y, Takata T, Ogawa I et al (2000a). p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells. Clin Cancer Res 6: 916-923.
79. Kudo Y, Takata T, Ogawa I et al (2000b). Reduced expression of p27(Kip1) correlates with an early stage of cancer invasion in oral squamous cell carcinoma. Cancer Lett 151: 217-222.
80. Kulkarni V, Saranath D (2004). Concurrent hypermethylation of multiple regulatory genes in chewing tobacco associated oral squamous cell carcinomas and adjacent normal tissues. Oral Oncol 40: 145-153.
81. Kuo MY, Hsu HY, Kok SH et al (2002). Prognostic role of p27(Kip1) expression in oral squamous cell carcinoma in Taiwan. Oral Oncol 38: 172-178.
82. Kushner J, Bradley G, Jordan RC (1997). Patterns of p53 and Ki-67 protein expression in epithelial dysplasia from the floor of the mouth. J Pathol 183: 418-423.
83. Lai S, El-Naggar AK (1999). Differential expression of key cell cycle genes (p16/cyclin D1/pRb) in head and neck squamous carcinomas. Lab Invest 79: 255-260.
84. Lee J, Kim SS (2009). The function of p27 KIP1 during tumor development. Exp Mol Med 41: 765-771.
85. Lee JJ, Hong WK, Hittelman WN et al (2000). Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 6: 1702-1710.
86. Li C, Shintani S, Terakado N et al (2005). Microvessel density and expression of vascular endothelial growth factor, basic fibroblast growth factor, and platelet-derived endothelial growth factor in oral squamous cell carcinomas. Int J Oral Maxillofac Surg 34: 559-565.
87. Li JN, Feng CJ, Lu YJ et al (2008). mRNA expression of the DNA replication-initiation proteins in epithelial dysplasia and squamous cell carcinoma of the tongue. BMC Cancer 8: 395.
88. Liao J, Mitsuyasu T, Yamane K, Ohishi M (2000). Telomerase activity in oral and maxillofacial tumors. Oral Oncol 36: 347-352.
89. Loro LL, Johannessen AC, Vintermyr OK (2002). Decreased expression of bcl-2 in moderate and severe oral epithelia dysplasias. Oral Oncol 38: 691-698.
90. Macluskey M, Chandrachud LM, Pazouki S et al (2000). Apoptosis, proliferation, and angiogenesis in oral tissues. Possible relevance to tumour progression. J Pathol 191: 368-375.
91. Mao L, Lee JS, Fan YH et al (1996). Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 2: 682-685.
92. Marshall CJ (1995). Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80: 179-185.
93. Massarelli E, Liu DD, Lee JJ et al (2005). Akt activation correlates with adverse outcome in tongue cancer. Cancer 104: 2430-2436.
94. Mehanna HM, Rattay T, Smith J, McConkey CC (2009). Treatment and follow-up of oral dysplasia - a systematic review and meta-analysis. Head Neck 31: 1600-1609.
95. Mineta H, Miura K, Takebayashi S et al (2000). Cyclin D1 overexpression correlates with poor prognosis in patients with tongue squamous cell carcinoma. Oral Oncol 36: 194-198.
96. Mishima K, Inoue K, Hayashi Y (2002). Overexpression of extracellular-signal regulated kinases on oral squamous cell carcinoma. Oral Oncol 38: 468-474.
97. Miyoshi Y, Tsukinoki K, Imaizumi T et al (1999). Telomerase activity in oral cancer. Oral Oncol 35: 283-289.
98. Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V, Gutkind JS (2009). Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol 45: 324-334.
99. Moriyama M, Kumagai S, Kawashiri S, Kojima K, Kakihara K, Yamamoto E (1997). Immunohistochemical study of tumour angiogenesis in oral squamous cell carcinoma. Oral Oncol 33: 369-374.
100. Muirhead DM, Hoffman HT, Robinson RA (2006). Correlation of clinicopathological features with immunohistochemical expression of cell cycle regulatory proteins p16 and retinoblastoma: distinct association with keratinisation and differentiation in oral cavity squamous cell carcinoma. J Clin Pathol 59: 711-715.
101. Murti PR, Warnakulasuriya KA, Johnson NW et al (1998). p53 expression in oral precancer as a marker for malignant potential. J Oral Pathol Med 27: 191-196.
102. Mutirangura A, Supiyaphun P, Trirekapan S et al (1996). Telomerase activity in oral leukoplakia and head and neck squamous cell carcinoma. Cancer Res 56: 3530-3533.
103. Nagatsuka H, Ishiwari Y, Tsujigiwa H, Nakano K, Nagai N (2001). Quantitation of epidermal growth factor receptor gene amplification by competitive polymerase chain reaction in pre-malignant and malignant oral epithelial lesions. Oral Oncol 37: 599-604.
104. el-Naggar AK, Hurr K, Batsakis JG, Luna MA, Goepfert H, Huff V (1995). Sequential loss of heterozygosity at microsatellite motifs in preinvasive and invasive head and neck squamous carcinoma. Cancer Res 55: 2656-2659.
105. Nagpal JK, Patnaik S, Das BR (2002). Prevalence of high-risk human papilloma virus types and its association with P53 codon 72 polymorphism in tobacco addicted oral squamous cell carcinoma (OSCC) patients of Eastern India. Int J Cancer 97: 649-653.
106. Nakahara Y, Shintani S, Mihara M, Kiyota A, Ueyama Y, Matsumura T (2000). Alterations of Rb, p16(INK4A) and cyclin D1 in the tumorigenesis of oral squamous cell carcinomas. Cancer Lett 160: 3-8.
107. Nemes JA, Nemes Z, Marton IJ (2005). p21WAF1/CIP1 expression is a marker of poor prognosis in oral squamous cell carcinoma. J Oral Pathol Med 34: 274-279.
108. Oliveira LR, Ribeiro-Silva A, Costa JP, Simoes AL, Matteo MA, Zucoloto S (2008). Prognostic factors and survival analysis in a sample of oral squamous cell carcinoma patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 106: 685-695.
109. Olshan AF, Weissler MC, Pei H, Conway K (1997). p53 mutations in head and neck cancer: new data and evaluation of mutational spectra. Cancer Epidemiol Biomarkers Prev 6: 499-504.
110. Pande P, Mathur M, Shukla NK, Ralhan R (1998). pRb and p16 protein alterations in human oral tumorigenesis. Oral Oncol 34: 396-403.
111. Pannone G, De Maria S, Zamparese R et al (2007). Prognostic value of human telomerase reverse transcriptase gene expression in oral carcinogenesis. Int J Oncol 30: 1349-1357.
112. Papadimitrakopoulou V, Izzo J, Lippman SM et al (1997). Frequent inactivation of p16INK4a in oral premalignant lesions. Oncogene 14: 1799-1803.
113. Partridge M, Emilion G, Pateromichelakis S, Phillips E, Langdon J (1997). Field cancerisation of the oral cavity: comparison of the spectrum of molecular alterations in cases presenting with both dysplastic and malignant lesions. Oral Oncol 33: 332-337.
114. Partridge M, Emilion G, Pateromichelakis S, A'Hern R, Phillips E, Langdon J (1998). Allelic imbalance at chromosomal loci implicated in the pathogenesis of oral precancer, cumulative loss and its relationship with progression to cancer. Oral Oncol 34: 77-83.
115. Partridge M, Pateromichelakis S, Phillips E, Emilion GG, A'Hern RP, Langdon JD (2000). A case-control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma within a field of cancerization. Cancer Res 60: 3893-3898.
116. Partridge M, Pateromichelakis S, Phillips E, Emilion G, Langdon J (2001). Profiling clonality and progression in multiple premalignant and malignant oral lesions identifies a subgroup of cases with a distinct presentation of squamous cell carcinoma. Clin Cancer Res 7: 1860-1866.
117. Pazouki S, Chisholm DM, Adi MM et al (1997). The association between tumour progression and vascularity in the oral mucosa. J Pathol 183: 39-43.
118. Pentenero M, Giaretti W, Navone R et al (2009). DNA aneuploidy and dysplasia in oral potentially malignant disorders: association with cigarette smoking and site. Oral Oncol 45: 887-890.
119. Poeta ML, Manola J, Goldwasser MA et al (2007). TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 357: 2552-2561.
120. Poh CF, Zhang L, Lam WL et al (2001). A high frequency of allelic loss in oral verrucous lesions may explain malignant risk. Lab Invest 81: 629-634.
121. Reed AL, Califano J, Cairns P et al (1996). High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 56: 3630-3633.
122. Ries LAGMD, Krapcho M, Stinchcomb DG et al (eds) (2008). SEER Cancer Statistics Review, 1975-2005. Bethesda, MD: National Cancer Institute.
123. Rosin MP, Epstein JB, Berean K et al (1997). The use of exfoliative cell samples to map clonal genetic alterations in the oral epithelium of high-risk patients. Cancer Res 57: 5258-5260.
124. Rosin MP, Cheng X, Poh C et al (2000). Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res 6: 357-362.
125. Rosin MP, Lam WL, Poh C et al (2002). 3p14 and 9p21 loss is a simple tool for predicting second oral malignancy at previously treated oral cancer sites. Cancer Res 62: 6447-6450.
126. Roz L, Wu CL, Porter S et al (1996). Allelic imbalance on chromosome 3p in oral dysplastic lesions: an early event in oral carcinogenesis. Cancer Res 56: 1228-1231.
127. Rubio Bueno P, Naval Gias L, Garcia Delgado R, Domingo Cebollada J, Diaz Gonzalez FJ (1998). Tumor DNA content as a prognostic indicator in squamous cell carcinoma of the oral cavity and tongue base. Head Neck 20: 232-239.
128. Saito T, Yamashita T, Notani K et al (1995). Flow cytometric analysis of nuclear DNA content in oral leukoplakia: relation to clinicopathologic findings. Int J Oral Maxillofac Surg 24: 44-47.
129. Schlecht NF (2005). Prognostic value of human papillomavirus in the survival of head and neck cancer patients: an overview of the evidence. Oncol Rep 14: 1239-1247.
130. Schoelch ML, Le QT, Silverman S Jr et al (1999a). Apoptosis-associated proteins and the development of oral squamous cell carcinoma. Oral Oncol 35: 77-85.
131. Schoelch ML, Regezi JA, Dekker NP et al (1999b). Cell cycle proteins and the development of oral squamous cell carcinoma. Oral Oncol 35: 333-342.
132. Seoane J, Bascones A, Asenjo JA, Garcia-Pola M, Varela-Centelles PI (1998). Flow cytometric analysis of nuclear DNA content in oral leukoplakia. Clin Otolaryngol Allied Sci 23: 136-140.
133. Shah NG, Trivedi TI, Tankshali RA et al (2007). Molecular alterations in oral carcinogenesis: significant risk predictors in malignant transformation and tumor progression. Int J Biol Markers 22: 132-143.
134. Shay JW, Wright WE (2010). Telomeres and telomerase in normal and cancer stem cells. FEBS Lett 584: 3819-3825.
135. Shin DM, Ro JY, Hong WK, Hittelman WN (1994). Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 54: 3153-3159.
136. Shin DM, Lee JS, Lippman SM et al (1996). p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst 88: 519-529.
137. Shintani S, Mihara M, Nakahara Y et al (2002). Expression of cell cycle control proteins in normal epithelium, premalignant and malignant lesions of oral cavity. Oral Oncol 38: 235-243.
138. Shintani S, Li C, Mihara M, Hino S, Nakashiro K, Hamakawa H (2003). Skp2 and Jab1 expression are associated with inverse expression of p27(KIP1) and poor prognosis in oral squamous cell carcinomas. Oncology 65: 355-362.
139. Shintani S, Li C, Ishikawa T, Mihara M, Nakashiro K, Hamakawa H (2004). Expression of vascular endothelial growth factor A, B, C, and D in oral squamous cell carcinoma. Oral Oncol 40: 13-20.
140. Smeenk L, Lohrum M (2010). Behind the scenes: unravelling the molecular mechanisms of p53 target gene selectivity (Review). Int J Oncol 37: 1061-1070.
141. Smith J, Rattay T, McConkey C, Helliwell T, Mehanna H (2009). Biomarkers in dysplasia of the oral cavity: a systematic review. Oral Oncol 45: 647-653.
142. Soni S, Kaur J, Kumar A et al (2005). Alterations of rb pathway components are frequent events in patients with oral epithelial dysplasia and predict clinical outcome in patients with squamous cell carcinoma. Oncology 68: 314-325.
143. Soria JC, Morat L, Commo F et al (2001). Telomerase activation cooperates with inactivation of p16 in early head and neck tumorigenesis. Br J Cancer 84: 504-511.
144. Srinivasan M, Jewell SD (2001). Evaluation of TGF-alpha and EGFR expression in oral leukoplakia and oral submucous fibrosis by quantitative immunohistochemistry. Oncology 61: 284-292.
145. Sumida T, Sogawa K, Hamakawa H, Sugita A, Tanioka H, Ueda N (1998). Detection of telomerase activity in oral lesions. J Oral Pathol Med 27: 111-115.
146. Suzuki H, Sugimura H, Hashimoto K (2006). p16INK4A in oral squamous cell carcinomas - a correlation with biological behaviors: immunohistochemical and FISH analysis. J Oral Maxillofac Surg 64: 1617-1623.
147. Szelachowska J, Dziegiel P, Jelen-Krzeszewska J et al (2006). Mcm-2 protein expression predicts prognosis better than Ki-67 antigen in oral cavity squamocellular carcinoma. Anticancer Res 26: 2473-2478.
148. Tabor MP, Brakenhoff RH, van Houten VM et al (2001). Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. Clin Cancer Res 7: 1523-1532.
149. Tabor MP, Braakhuis BJ, van der Wal JE et al (2003). Comparative molecular and histological grading of epithelial dysplasia of the oral cavity and the oropharynx. J Pathol 199: 354-360.
150. Tae K, El-Naggar AK, Yoo E et al (2000). Expression of vascular endothelial growth factor and microvessel density in head and neck tumorigenesis. Clin Cancer Res 6: 2821-2828.
151. Takeda T, Sugihara K, Hirayama Y, Hirano M, Tanuma JI, Semba I (2006). Immunohistological evaluation of Ki-67, p63, CK19 and p53 expression in oral epithelial dysplasias. J Oral Pathol Med 35: 369-375.
152. Takeshima M, Saitoh M, Kusano K et al (2008). High frequency of hypermethylation of p14, p15 and p16 in oral pre-cancerous lesions associated with betel-quid chewing in Sri Lanka. J Oral Pathol Med 37: 475-479.
153. Taoudi Benchekroun M, Saintigny P, Thomas SM et al (2010). Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila) 3: 800-809.
154. Temam S, Flahault A, Perie S et al (2000). p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol 18: 385-394.
155. Thurfjell N, Coates PJ, Boldrup L et al (2005). Function and importance of p63 in normal oral mucosa and squamous cell carcinoma of the head and neck. Adv Otorhinolaryngol 62: 49-57.
156. Todd R, Hinds PW, Munger K et al (2002). Cell cycle dysregulation in oral cancer. Crit Rev Oral Biol Med 13: 51-61.
157. Torres-Rendon A, Roy S, Craig GT, Speight PM (2009a). Expression of Mcm2, geminin and Ki67 in normal oral mucosa, oral epithelial dysplasias and their corresponding squamous-cell carcinomas. Br J Cancer 100: 1128-1134.
158. Torres-Rendon A, Stewart R, Craig GT, Wells M, Speight PM (2009b). DNA ploidy analysis by image cytometry helps to identify oral epithelial dysplasias with a high risk of malignant progression. Oral Oncol 45: 468-473.
159. Tsui IF, Rosin MP, Zhang L, Ng RT, Lam WL (2008). Multiple aberrations of chromosome 3p detected in oral premalignant lesions. Cancer Prev Res (Phila) 1: 424-429.
160. Tsui IF, Poh CF, Garnis C, Rosin MP, Zhang L, Lam WL (2009). Multiple pathways in the FGF signaling network are frequently deregulated by gene amplification in oral dysplasias. Int J Cancer 125: 2219-2228.
161. Turatti E, da Costa Neves A, de Magalhaes MH, de Sousa SO (2005). Assessment of c-Jun, c-Fos and cyclin D1 in premalignant and malignant oral lesions. J Oral Sci 47: 71-76.
162. Venkatesan TK, Kuropkat C, Caldarelli DD et al (1999). Prognostic significance of p27 expression in carcinoma of the oral cavity and oropharynx. Laryngoscope 109: 1329-1333.
163. Vered M, Allon I, Dayan D (2009). Maspin, p53, p63, and Ki-67 in epithelial lesions of the tongue: from hyperplasia through dysplasia to carcinoma. J Oral Pathol Med 38: 314-320.
164. Vousden KH, Lane DP (2007). p53 in health and disease. Nat Rev Mol Cell Biol 8: 275-283.
165. Warnakulasuriya S, Jia C, Johnson N, Houghton J (2000). p53 and P-glycoprotein expression are significant prognostic markers in advanced head and neck cancer treated with chemo/radiotherapy. J Pathol 191: 33-38.
166. Warnakulasuriya S, Reibel J, Bouquot J, Dabelsteen E (2008). Oral epithelial dysplasia classification systems: predictive value, utility, weaknesses and scope for improvement. J Oral Pathol Med 37: 127-133.
167. Watanabe S, Sato K, Okazaki Y, Tonogi M, Tanaka Y, Yamane GY (2009). Activation of PI3K-AKT pathway in oral epithelial dysplasia and early cancer of tongue. Bull Tokyo Dent Coll 50: 125-133.
168. Watanabe S, Watanabe R, Oton-Leite AF et al (2010). Analysis of cell proliferation and pattern of invasion in oral squamous cell carcinoma. J Oral Sci 52: 417-424.
169. Wong TS, Man MW, Lam AK, Wei WI, Kwong YL, Yuen AP (2003). The study of p16 and p15 gene methylation in head and neck squamous cell carcinoma and their quantitative evaluation in plasma by real-time PCR. Eur J Cancer 39: 1881-1887.
170. Xie X, De Angelis P, Clausen OP, Boysen M (1999). Prognostic significance of proliferative and apoptotic markers in oral tongue squamous cell carcinomas. Oral Oncol 35: 502-509.
171. Xie X, Clausen OP, Boysen M (2002). Prognostic significance of p21WAF1/CIP1 expression in tongue squamous cell carcinomas. Arch Otolaryngol Head Neck Surg 128: 897-902.
172. Xu J, Gimenez-Conti IB, Cunningham JE et al (1998). Alterations of p53, cyclin D1, Rb, and H-ras in human oral carcinomas related to tobacco use. Cancer 83: 204-212.
173. Yajima Y, Noma H, Furuya Y et al (2004). Quantification of telomerase activity of regions unstained with iodine solution that surround oral squamous cell carcinoma. Oral Oncol 40: 314-320.
174. Ye Y, Lippman SM, Lee JJ et al (2008). Genetic variations in cell-cycle pathway and the risk of oral premalignant lesions. Cancer 113: 2488-2495.
175. Yoo GH, Xu HJ, Brennan JA et al (1994). Infrequent inactivation of the retinoblastoma gene despite frequent loss of chromosome 13q in head and neck squamous cell carcinoma. Cancer Res 54: 4603-4606.
176. Youssef EM, Lotan D, Issa JP et al (2004). Hypermethylation of the retinoic acid receptor-beta(2) gene in head and neck carcinogenesis. Clin Cancer Res 10: 1733-1742.
177. Zhang L, Zhang W (1999). Telomerase hTR and hTRT gene expression in oral precancerous lesions and squamous cell carcinomas. Chin J Dent Res 2: 43-48.
178. Zhang L, Cheung KJ Jr, Lam WL et al (2001a). Increased genetic damage in oral leukoplakia from high risk sites: potential impact on staging and clinical management. Cancer 91: 2148-2155.
179. Zhang L, Poh CF, Lam WL et al (2001b). Impact of localized treatment in reducing risk of progression of low-grade oral dysplasia: molecular evidence of incomplete resection. Oral Oncol 37: 505-512.
180. Zhang L, Williams M, Poh CF et al (2005). Toluidine blue staining identifies high-risk primary oral premalignant lesions with poor outcome. Cancer Res 65: 8017-8021.